{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T01:21:03Z","timestamp":1793755263454,"version":"4.6.1"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T00:00:00Z","timestamp":1748995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T00:00:00Z","timestamp":1748995200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cost Eff Resour Alloc"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Early intervention to slow childhood progression of myopia may improve quality of life and prevent future complications that burden individuals and healthcare systems. This study assessed the cost-effectiveness of myopia-control spectacles and contact lenses for the reduction of myopia progression among children and adolescents in Wales.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A cost-utility analysis compared peripheral plus spectacle lenses (PPSL), multifocal soft contact lenses (MFSCL) and orthokeratology against single-vision correction. Efficacy and safety were informed by a Cochrane systemic review and meta-analyses. Quality-adjusted life years (QALYs) and costs incurred by NHS Wales were modelled over a lifetime horizon and discounted at 3.5%. Sensitivity analyses estimated uncertainty in incremental cost-effectiveness ratios (ICERs).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>PPSL was estimated to provide minimal benefit at a higher cost than single-vision correction. MFSCL gave a 0.28 QALY improvement at an additional cost of \u00a34,040; corresponding to an ICER of \u00a38,367 versus single-vision correction. Orthokeratology provided 0.5 QALYs at an additional cost of \u00a33,732; corresponding to an ICER of \u00a33,995 versus single-vision correction. In probabilistic sensitivity analysis, ICERs were below \u00a320,000 in 71% and 90% of simulations for MFSCL and orthokeratology, respectively. Orthokeratology was the most cost-effective strategy in 76% of simulations. Cost-effectiveness was influenced by changes in progression rates, intervention costs and the utility of high myopia. However, orthokeratology remained the most cost-effective strategy throughout.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>MFSCL and orthokeratology may be cost-effective options to slow the progression of myopia at thresholds applied in the UK. Further research is needed to understand the long-term effects of myopia-control interventions and their impact on quality of life.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12962-025-00632-w","type":"journal-article","created":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T14:31:45Z","timestamp":1749047505000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Cost-effectiveness of myopia-control spectacles and contact lenses for children and adolescents in Wales"],"prefix":"10.1186","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-0686-6795","authenticated-orcid":false,"given":"Hayley","family":"Bennett","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andy","family":"Britton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"O\u2019Sullivan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Lado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,4]]},"reference":[{"issue":"1","key":"632_CR1","doi-asserted-by":"publisher","first-page":"e0146332","DOI":"10.1371\/journal.pone.0146332","volume":"11","author":"SJ McCullough","year":"2016","unstructured":"McCullough SJ, O\u2019Donoghue L, Saunders KJ. Six year refractive change among white children and young adults: evidence for significant increase in myopia among white UK children. PLoS ONE. 2016;11(1):e0146332.","journal-title":"PLoS ONE"},{"issue":"7","key":"632_CR2","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1136\/bjophthalmol-2015-307724","volume":"100","author":"AR Rudnicka","year":"2016","unstructured":"Rudnicka AR, Kapetanakis VV, Wathern AK, Logan NS, Gilmartin B, Whincup PH, et al. Global variations and time trends in the prevalence of childhood myopia, a systematic review and quantitative meta-analysis: implications for aetiology and early prevention. Br J Ophthalmol. 2016;100(7):882\u201390.","journal-title":"Br J Ophthalmol"},{"issue":"6","key":"632_CR3","first-page":"1232","volume":"42","author":"CJ Hammond","year":"2001","unstructured":"Hammond CJ, Snieder H, Gilbert CE, Spector TD. Genes and environment in refractive error: the twin eye study. Invest Ophthalmol Vis Sci. 2001;42(6):1232\u20136.","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"8","key":"632_CR4","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1136\/bjophthalmol-2018-312439","volume":"103","author":"KM Williams","year":"2019","unstructured":"Williams KM, Kraphol E, Yonova-Doing E, Hysi PG, Plomin R, Hammond CJ. Early life factors for myopia in the British twins early development study. Br J Ophthalmol. 2019;103(8):1078\u201384.","journal-title":"Br J Ophthalmol"},{"issue":"9","key":"632_CR5","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1136\/bjo.84.9.1031","volume":"84","author":"K Rose","year":"2000","unstructured":"Rose K, Harper R, Tromans C, Waterman C, Goldberg D, Haggerty C, et al. Quality of life in myopia. Br J Ophthalmol. 2000;84(9):1031\u20134.","journal-title":"Br J Ophthalmol"},{"issue":"11","key":"632_CR6","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.1016\/j.ophtha.2021.04.032","volume":"128","author":"MA Bullimore","year":"2021","unstructured":"Bullimore MA, Ritchey ER, Shah S, Leveziel N, Bourne RRA, Flitcroft DI. The risks and benefits of myopia control. Ophthalmology. 2021;128(11):1561\u201379.","journal-title":"Ophthalmology"},{"issue":"4","key":"632_CR7","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1167\/iovs.61.4.49","volume":"61","author":"AEG Haarman","year":"2020","unstructured":"Haarman AEG, Enthoven CA, Tideman JWL, Tedja MS, Verhoeven VJM, Klaver CCW. The complications of myopia: a review and meta-analysis. Invest Ophthalmol Vis Sci. 2020;61(4):49.","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"6","key":"632_CR8","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1097\/OPX.0000000000001367","volume":"96","author":"MA Bullimore","year":"2019","unstructured":"Bullimore MA, Brennan NA. Myopia control: why each diopter matters. Optom Vis Sci. 2019;96(6):463\u20135.","journal-title":"Optom Vis Sci"},{"key":"632_CR9","unstructured":"World Council of Optometry. The standard of care for myopia management by optometrists (World Council of Optometry Resolution): World Council of Optometry. 2021 [18 Apr 2023]. Available from: https:\/\/worldcouncilofoptometry.info\/resolution-the-standard-of-care-for-myopia-management-by-optometrists\/"},{"key":"632_CR10","unstructured":"College of Optometrists. Childhood-onset myopia management: guidance for optometrists: The College of Optometrists; 2022 [18 April 2023]. Available from: https:\/\/www.college-optometrists.org\/category-landing-pages\/clinical-topics\/myopia\/myopia-management-%E2%80%93-guidance-for-optometrists#Management"},{"key":"632_CR11","unstructured":"Health Technology Wales. Myopia-control contact lenses and spectacles to slow the progression of myopia in children and adolescents 2023 [06 Nov 2023]. Available from: https:\/\/healthtechnology.wales\/reports-guidance\/control-contact-lenses-and-spectacles\/"},{"issue":"8","key":"632_CR12","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1136\/bjophthalmol-2021-320318","volume":"107","author":"TR Fricke","year":"2023","unstructured":"Fricke TR, Sankaridurg P, Naduvilath T, Resnikoff S, Tahhan N, He M, et al. Establishing a method to estimate the effect of antimyopia management options on lifetime cost of myopia. Br J Ophthalmol. 2023;107(8):1043.","journal-title":"Br J Ophthalmol"},{"key":"632_CR13","doi-asserted-by":"crossref","unstructured":"Lawrenson JG, Shah R, Huntjens B, Downie LE, Virgili G, Dhakal R et al. Interventions for myopia control in children: a living systematic review and network meta-analysis. Cochrane Database Syst Reviews. 2023;Issue 2:Art. No.: CD014758.","DOI":"10.1002\/14651858.CD014758.pub2"},{"key":"632_CR14","unstructured":"Royal National Institute of Blind People. Myopia and pathological myopia factsheet. 2022 [Available from: www.rnib.org.uk\/your-eyes\/eye-conditions-az\/myopia-and-pathological-myopia\/"},{"issue":"4","key":"632_CR15","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1111\/ceo.12206","volume":"42","author":"GL Kanthan","year":"2014","unstructured":"Kanthan GL, Mitchell P, Rochtchina E, Cumming RG, Wang JJ. Myopia and the long-term incidence of cataract and cataract surgery: the blue mountains eye study. Clin Exp Ophthalmol. 2014;42(4):347\u201353.","journal-title":"Clin Exp Ophthalmol"},{"key":"632_CR16","unstructured":"Health Technology Wales. Appraisal Process Guide 2023 [Available from: https:\/\/healthtechnology.wales\/about\/our-appraisal-process\/"},{"issue":"1","key":"632_CR17","doi-asserted-by":"publisher","first-page":"Article101517","DOI":"10.1016\/j.clae.2021.101517","volume":"46","author":"Z Chen","year":"2023","unstructured":"Chen Z, Zhang Z, Xue F, Zhou J, Zeng L, Qu X, et al. The relationship between myopia progression and axial elongation in children wearing orthokeratology contact lenses. Contact lens Anterior Eye. 2023;46(1):Article101517.","journal-title":"Contact lens Anterior Eye"},{"issue":"7","key":"632_CR18","doi-asserted-by":"publisher","first-page":"e1249","DOI":"10.1111\/aos.14736","volume":"99","author":"TM Jakobsen","year":"2021","unstructured":"Jakobsen TM, Gehr NL, M\u00f8ller F. Correlation between change in cycloplegic spherical equivalent refractive error and change in axial length in Danish children aged 6 to 12 year. Acta Ophthalmol. 2021;99(7):e1249\u201350.","journal-title":"Acta Ophthalmol"},{"key":"632_CR19","unstructured":"BNF. Ranibizumab [specialist drug]: medicinal forms 2023 [05 July 2023]. Available from: https:\/\/bnf.nice.org.uk\/drugs\/ranibizumab\/medicinal-forms\/"},{"key":"632_CR20","unstructured":"NHS England. National Cost Collection for the NHS 2020\/21: National Health Service. 2022 [11 Aug 2022]. Available from: https:\/\/www.england.nhs.uk\/costing-in-the-nhs\/national-cost-collection\/"},{"key":"632_CR21","unstructured":"NICE, Glaucoma. diagnosis and management [Original Publication Date: 01 Nov 2017; Last updated: 26 Jan 2022]: National Institute for Health and Care Excellence; 2022 [6 Feb 2023]. Available from: https:\/\/www.nice.org.uk\/guidance\/ng81"},{"issue":"1","key":"632_CR22","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.ajo.2013.08.010","volume":"157","author":"TY Wong","year":"2014","unstructured":"Wong TY, Ferreira A, Hughes R, Carter G, Mitchell P. Epidemiology and disease burden of pathologic myopia and myopic choroidal neovascularization: an evidence-based systematic review. Am J Ophthalmol. 2014;157(1):9\u2013e2512.","journal-title":"Am J Ophthalmol"},{"key":"632_CR23","unstructured":"Jones KC, Weatherley H, Birch S. Unit costs of health and social care 2022: Personal Social Services Research Unit (University of Kent) & Centre for Health Economics (University of York), Kent, UK; 2023 [07 Feb 2023]. Available from: https:\/\/www.pssru.ac.uk\/unitcostsreport\/"},{"key":"632_CR24","unstructured":"Hern\u00e1ndez Alava M, Pudney S, Wailoo A, Estimating. EQ-5D by age and sex for the UK 2022 [25 Oct 2022]. Available from: https:\/\/www.sheffield.ac.uk\/nice-dsu\/methods-development\/estimating-eq-5d"},{"key":"632_CR25","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.2147\/OPTH.S362342","volume":"16","author":"CA-O Hong","year":"2022","unstructured":"Hong CA-O, Boyd MA-O, Wilson G, Hong SC. Photorefraction screening plus Atropine treatment for myopia is cost-effective: a proof-of-concept Markov analysis. Clin Ophthalmol. 2022;16:1941\u201352.","journal-title":"Clin Ophthalmol"},{"key":"632_CR26","unstructured":"WHO. WHO methods and data sources for global burden of disease estimates 2000\u20132019: World Health Organization. 2020 [20 Dec 2022]. Available from: https:\/\/cdn.who.int\/media\/docs\/default-source\/gho-documents\/global-health-estimates\/ghe2019_daly-methods.pdf?sfvrsn=31b25009_7"},{"issue":"3","key":"632_CR27","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1016\/S0161-6420(01)00971-X","volume":"109","author":"BG Busbee","year":"2002","unstructured":"Busbee BG, Brown MM, Brown GC, Sharma S. Incremental cost-effectiveness of initial cataract surgery. Ophthalmology. 2002;109(3):606\u201312.","journal-title":"Ophthalmology"},{"key":"632_CR28","first-page":"301","volume":"99","author":"HD Jampel","year":"2001","unstructured":"Jampel HD. Glaucoma patients\u2019 assessment of their visual function and quality of life. Trans Am Ophthalmol Soc. 2001;99:301\u201317.","journal-title":"Trans Am Ophthalmol Soc"},{"issue":"12","key":"632_CR29","doi-asserted-by":"publisher","first-page":"6270","DOI":"10.1167\/iovs.10-5528","volume":"51","author":"AR Rudnicka","year":"2010","unstructured":"Rudnicka AR, Owen CG, Nightingale CM, Cook DG, Whincup PH. Ethnic differences in the prevalence of myopia and ocular biometry in 10- and 11-year-old children: the child heart and health study in England (CHASE). Invest Ophthalmol Vis Sci. 2010;51(12):6270\u20136.","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"11","key":"632_CR30","doi-asserted-by":"publisher","first-page":"e712","DOI":"10.1016\/S2214-109X(15)00069-8","volume":"3","author":"JA Salomon","year":"2015","unstructured":"Salomon JA, Haagsma JA, Davis A, de Noordhout CM, Polinder S, Havelaar AH, et al. Disability weights for the global burden of disease 2013 study. Lancet Global Health. 2015;3(11):e712\u201323.","journal-title":"Lancet Global Health"},{"key":"632_CR31","doi-asserted-by":"crossref","unstructured":"Rappon J, Chung C, Young G, Hunt C, Neitz J, Neitz M et al. Control of myopia using diffusion optics spectacle lenses: 12-month results of a randomised controlled, efficacy and safety study (CYPRESS). Br J Ophthalmol. 2022:Published Online First: 01 September 2022.","DOI":"10.1136\/bjo-2021-321005"},{"issue":"11","key":"632_CR32","doi-asserted-by":"publisher","first-page":"e2340986","DOI":"10.1001\/jamanetworkopen.2023.40986","volume":"6","author":"S Agyekum","year":"2023","unstructured":"Agyekum S, Chan PP, Adjei PE, Zhang Y, Huo Z, Yip BHK, et al. Cost-Effectiveness analysis of myopia progression interventions in children. JAMA Netw Open. 2023;6(11):e2340986.","journal-title":"JAMA Netw Open"},{"issue":"Suppl 7","key":"632_CR33","first-page":"34","volume":"29","author":"J Lian","year":"2023","unstructured":"Lian J, McGhee SM, Yap MKH, Sum R. Cost-effectiveness of myopia control by use of defocus incorporated multiple segments lenses: abridged secondary publication. Hong Kong Med J. 2023;29(Suppl 7):34\u20136.","journal-title":"Hong Kong Med J"},{"key":"632_CR34","doi-asserted-by":"publisher","first-page":"04183","DOI":"10.7189\/jogh.14.04183","volume":"14","author":"C So","year":"2024","unstructured":"So C, Lian J, McGhee SM, Sum RWM, Lam AKC, Yap MKH. Lifetime cost-effectiveness of myopia control intervention for the children population. J Glob Health. 2024;14:04183.","journal-title":"J Glob Health"},{"key":"632_CR35","doi-asserted-by":"publisher","first-page":"M132","DOI":"10.1167\/iovs.18-25955","volume":"60","author":"JS Wolffsohn","year":"2019","unstructured":"Wolffsohn JS, Kollbaum PS, Berntsen DA, Atchison DA, Benavente A, Bradley A, et al. IMI - clinical myopia control trials and instrumentation report. Invest Ophthalmol Vis Sci. 2019;60:M132\u201360.","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"12","key":"632_CR36","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1080\/02713683.2023.2250581","volume":"48","author":"X Han","year":"2023","unstructured":"Han X, Ruan X, Zhang Y, Lin H, Zhang M, Tan X, et al. Effect of myopia severity on the Health-Related quality of life in children and their parents. Curr Eye Res. 2023;48(12):1189\u201394.","journal-title":"Curr Eye Res"},{"issue":"5","key":"632_CR37","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1016\/j.ophtha.2016.01.006","volume":"123","author":"BA Holden","year":"2016","unstructured":"Holden BA, Fricke TR, Wilson DA, Jong M, N KS, Sankaridurg P, et al. Global prevalence of myopia and high myopia and Temporal trends from 2000 through 2050. Ophthalmology. 2016;123(5):1036\u201342.","journal-title":"Ophthalmology"}],"container-title":["Cost Effectiveness and Resource Allocation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12962-025-00632-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12962-025-00632-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12962-025-00632-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T14:31:50Z","timestamp":1749047510000},"score":1,"resource":{"primary":{"URL":"https:\/\/resource-allocation.biomedcentral.com\/articles\/10.1186\/s12962-025-00632-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,4]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["632"],"URL":"https:\/\/doi.org\/10.1186\/s12962-025-00632-w","relation":{},"ISSN":["1478-7547"],"issn-type":[{"value":"1478-7547","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,4]]},"assertion":[{"value":"2 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable, because the study did not involve human participants or patient data.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"HB and FL have no competing interests. AB and DO are directors of branches of Specsavers. AB\u2019s branch of opticians acted as a trial practice for the launch of myopia-control technologies, MiSight and MiyoSmart.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"26"}}